Immunoglobulin replacement products in current clinical use in the United States have poor neutralizing activity against SARS-CoV-2 Omicron strains

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now